Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Detaylı Bibliyografya
Asıl Yazarlar:	Shrimanker, R, Pavord, I, Price, R, Bradford, E, Keene, O, Yancey, S
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	American Thoracic Society 2018

Benzer Materyaller

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Yazar:: Gunsoy, N, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Yazar:: Steven W. Yancey, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Yazar:: Howell, I, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Yazar:: Bel, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Yazar:: Ortega, H, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Yazar:: Bel, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Mepolizumab in refractory eosinophilic asthma.
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Yazar:: Imran Howell, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Mepolizumab for eosinophilic COPD
Yazar:: Sciurba, F, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
Yazar:: Price, D, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Yazar:: Yancey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
Yazar:: Jiang-Hua Li, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
Yazar:: David B. Price, ve diğerleri
Baskı/Yayın Bilgisi: (2019-08-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Yazar:: Pavord, I
Baskı/Yayın Bilgisi: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Yazar:: Ortega, H, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Yazar:: Haldar, P, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Biomarkers for severe eosinophilic asthma.
Yazar:: Yancey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Yazar:: Moran, AM, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Yazar:: Ian D. Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
Yazar:: Arian Ghassemian, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma
Yazar:: Jie Gao, ve diğerleri
Baskı/Yayın Bilgisi: (2018-05-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Yazar:: Terufumi Shimoda, ve diğerleri
Baskı/Yayın Bilgisi: (2017-07-01)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
Yazar:: Connolly, CM, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Yazar:: Prazma CM, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
Yazar:: Gao J, ve diğerleri
Baskı/Yayın Bilgisi: (2018-04-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Yazar:: Menzella F, ve diğerleri
Baskı/Yayın Bilgisi: (2016-06-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
Yazar:: Charlene M. Prazma, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Yazar:: Chio Sakai, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
Yazar:: Berry, M, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Yazar:: Wechsler, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
Yazar:: Buendía, JA, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
Yazar:: Jefferson Antonio Buendía, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts
Yazar:: Yuki Hoshino, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)